AATD patients can be treated with AAT augmentation therapy which results in decreased levels of AαVal541, a peptide marker generated by the cleavage of fibrinogen by PR3 (Schouten et al., 2021). Here, PRTN3 is linked to alpha 1-antitrypsin deficiency.